PALO ALTO, Calif., Jan. 4 /PRNewswire/ --
Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomics information company
announced today that its presentation at the JPMorgan H&Q Healthcare
Conference will be webcast live by JP Morgan and can be accessed by
registering at
http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html .
Paul A. Friedman, M.D., Chief Executive Officer and Robert Stein, M.D.,
Ph.D., President and Chief Scientific Officer will present an overview of the
company and its business strategy. The presentation is scheduled to be
delivered at 4:00 p.m. PST on Monday, January 7, 2002 from the Grand Ballroom
of the Westin St. Francis Hotel in San Francisco.
Incyte Genomics, Inc. has developed the leading integrated platform of
genomic technologies designed to aid in the understanding of the molecular
basis of disease. Incyte develops and markets genomic databases and
partnership programs, related reagents and services. These products, programs
and services assist pharmaceutical and biotechnology researchers with all
phases of drug discovery and development including gene discovery,
understanding disease pathways, identifying new disease targets and the
discovery and correlation of gene sequence variation to disease. In addition,
Incyte has the largest portfolio of issued United States patents covering
human full-length genes and the proteins they encode and is leveraging its
intellectual property position to be a leader in therapeutic discoveries. For
more information, visit Incyte's web site at http://www.incyte.com .
Except for the historical information contained herein, the matters set
forth in this press release, are forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially. For a
discussion of factors that may cause results to differ, see Incyte's SEC
reports, including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2001. Incyte disclaims any intent or obligation to update these
forward-looking statements.
CONTACT: Paul Chirico, Investor Relations & Corporate Communications of
Incyte Genomics, Inc., +1-650-845-4589.
SOURCE Incyte Genomics, Inc.
 back to top
Related links:
http://www.incyte.com
CONTACT:
Paul Chirico, Investor Relations & Corporate
Communications of Incyte Genomics, Inc., +1-650-845-4589
|
